![](https://www.recercasantpau.cat/wp-content/uploads/2019/03/edifici-web-190x160.jpg)
28/03/2019
Sant Pau’s Hematology will participate in the clinical phase I / II research with CART CD44v6 cells in acute myeloid leukemia and multiple myeloma
MolMed SpA. (MLMD.MI), a biotechnology company focused on the research, development, production and clinical validation of genes and cells therapies for the treatment of cancer and rare diseases, anno...